Holen Sie sich die Stockscreener-App
9.21
1.07%
-0.10
Handel nachbörslich:
9.21
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Under Pressure Amid Biotech Volatility - AD HOC NEWS
Prothena Corp plc Stock (ISIN: IE00B91XRN20) Faces Pressure Amid Biotech Volatility - AD HOC NEWS
Citizens reaffirms Prothena stock rating on Novo Nordisk milestone - Investing.com UK
Prothena earns $50M milestone from Novo Nordisk for drug trial - Investing.com Nigeria
IPO Launch: Will Prothena Corporation plc outperform tech stocks2026 Movers & Weekly High Return Forecasts - baoquankhu1.vn
Prothena (NASDAQ:PRTA) Share Price Passes Above 50-Day Moving AverageTime to Sell? - MarketBeat
Discipline and Rules-Based Execution in PRTA Response - Stock Traders Daily
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related t - PharmiWeb.com
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena Corporation Plc Receives $50 Million Clinical Milestone Payment From Novo Nordisk - marketscreener.com
Is Prothena Corporation plc stock a dividend growth opportunity2025 Buyback Activity & Real-Time Buy Zone Alerts - Naître et grandir
Aug Reactions: Is Prothena Corporation plc attractive for institutional investors - baoquankhu1.vn
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution (NASDAQ:PRTA) - Seeking Alpha
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade - Finviz
Prothena (NASDAQ:PRTA) Shares Up 8.7%Still a Buy? - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of “Hold” by Analysts - Defense World
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Prothena Corporation plc (PRTA) Stock Analysis: Navigating a 137% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Prothena Announces $100 Million Share Repurchase Program - TipRanks
Prothena authorizes $100 million share buyback program - Investing.com South Africa
Prothena Corporation plc announces an Equity Buyback for $100 million worth of its shares. - marketscreener.com
Prothena (NASDAQ: PRTA) okays $100M share buyback through 2026 - Stock Titan
Prothena Approves $100 Million Share Buyback Authorization - marketscreener.com
Prothena stock jumps on $100M share buyback authorization By Investing.com - Investing.com UK
Prothena Corporation plc (NASDAQ: PRTA) clears shelf to sell up to $200M in shares - Stock Titan
Prothena Announces up to $100 Million Share Repurchase Plan - The Joplin Globe
PROTHENA CORP PUBLIC LTD CO SEC 10-K Report - TradingView
Prothena (NASDAQ: PRTA) reshapes pipeline and cuts staff in 10-K - Stock Titan
Prothena Corporation plc authorizes a Buyback Plan. - marketscreener.com
Behavioral Patterns of PRTA and Institutional Flows - Stock Traders Daily
FY2026 EPS Estimates for Prothena Boosted by HC Wainwright - MarketBeat
Royal Bank Of Canada Increases Prothena (NASDAQ:PRTA) Price Target to $12.00 - Defense World
RBC Capital Raises Price Target for Prothena Corp (PRTA) to $12. - GuruFocus
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
Prothena (NASDAQ:PRTA) Price Target Raised to $12.00 - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript - Insider Monkey
Prothena Corporation plc Q4 2025 Earnings Call Summary - Yahoo Finance
Prothena Corp PLC (PRTA) Q4 2025 Earnings Call Highlights: Strat - GuruFocus
Prothena Q4 Earnings Call Highlights - MarketBeat
Can Prothena Corporation plc be recession proofTrade Exit Summary & Growth Focused Stock Reports - mfd.ru
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Prothena (PRTA) Projects Financial Outlook and Clinical Milestones - GuruFocus
Prothena Corporation plc announced that the company has the potential to receive up to $105 million in cumulative clinical milestone payments by the end of 2026. - Bitget
Prothena (NASDAQ:PRTA) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights - The Joplin Globe
Exploring Prothena Corp's Earnings Expectations - Benzinga
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? - Finviz
(PRTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Will Prothena Corporation plc stock remain a Wall Street favoriteQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - mfd.ru
Prothena Corporation plc (PRTA) Stock Analysis: Exploring a 129.76% Potential Upside in Biotechnology - DirectorsTalk Interviews
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - pharmiweb.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):